|
Clinical application of oligodendrocyte precursor cells for cell-based therapy
Naohiro Egawa1, Hajime Takase2, Lok Josephine3, Ryosuke Takahashi4, Ken Arai2
1 Department of Radiology and Neurology, Neuroprotection Research Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
2 Department of Radiology and Neurology, Neuroprotection Research Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, USA
3 Department of Radiology and Neurology, Neuroprotection Research Laboratory, Massachusetts General Hospital, Harvard Medical School; Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
4 Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Correspondence Address:
Naohiro Egawa
Department of Neurology, Kyoto University Graduate School of Medicine, 54 Shogoin.Kawaharacho, Sakyoku, Kyoto 606-8507, Japan
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2394-8108.192515
|
|
Oligodendrocyte precursor cells (OPCs), which give rise to mature oligodendrocytes (OLs), play important roles in maintaining white matter function. Even during the adulthood period, OPCs comprise roughly 5% of all cells in the forebrain and retain a capability to become myelinated OLs. Recently, OPCs have been proposed as a novel source for cell-based therapy. For the purpose, OPCs can be obtained from embryonic stem cells, induced pluripotent stem cells, and directly converted cells derived from patients. Here, we will provide a brief review of the potential of using OPCs as a cell-based therapy for treating various neurological diseases. |
